Eli Lilly's investigational drug, retatrutide, has demonstrated significant efficacy in weight loss during a phase 3 clinical trial. Patients receiving the highest dose lost an average of 28.3% of their body weight, equating to about 70.3 pounds over 80 weeks, compared to just 2.2% in the placebo group. Notably, 65% of participants on this dose achieved a body mass index (BMI) below 30, indicating a shift from obesity status. In an extended trial lasting 104 weeks, patients with a BMI of 35 or higher lost an average of 85 pounds, reflecting a 30% reduction in body weight. However, the drug's effectiveness comes with a higher risk of side effects; 11% of patients discontinued due to adverse events, with 40% experiencing nausea and 25% vomiting. The trial results, which have not yet been peer-reviewed, will be presented at the upcoming 86th annual American Diabetes Association Scientific Sessions. Retatrutide targets three hormones associated with weight management, positioning it as a potentially leading treatment in the GLP-1 drug class.